arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CRESCENT BIOPHARMA, INC.

CBIO
$16.79 ▲ +0.32 (+1.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

CRESCENT BIOPHARMA, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -12.8%
FCF / Share None
Trailing P/E
Price / Book 2.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-23.28M
↓ -53.7%
Operating Margin Operating profit as % of sales
-90.1%
↓ -273.8%
FCF / Share Free cash flow per share
$-7.91
↑ +51.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 56 quarters